Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Aminosidine
2. Beta-d-glucopyranosyl-isomer Paromomycin
3. Catenulin
4. Estomycin
5. Gabbromycin
6. Humatin
7. Hydroxymycin
8. Neomycin E
9. Paramomycin
10. Paromomycin I
11. Paromomycin Phosphate
12. Paromomycin Sulfate
13. Paromomycin Sulfate (1:1)
14. Paromomycin Sulfate (2:5)
15. Paromomycin, Beta D Glucopyranosyl Isomer
16. Paromomycin, Beta-d-glucopyranosyl-isomer
1. Aminosidin
2. Catenulin
3. Neomycin E
4. Hydroxymycin
5. Aminosidine
6. Monomycin A
7. Crestomycin
8. Estomycin
9. Paucimycin
10. 7542-37-2
11. Paromomycin I
12. Zygomycin A1
13. Paromomycine
14. Gabromycin
15. Humatin
16. Quintomycin C
17. Paramomycin Sulfate
18. Paromomicina
19. Paromomycinum
20. Paucimycinum
21. Antibiotic 503-3
22. Gabbromycin
23. Paromomycin [inn]
24. Antibiotic Sf 767b
25. Gabbromicina
26. Paromomycin (inn)
27. R 400
28. (1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside
29. 61jjc8n5zk
30. Antibiotic Sf-767b
31. Amminosidin
32. Humycin
33. Aminosidine I
34. Chebi:7934
35. (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
36. R-400
37. Antibiotic 2230d
38. Paramomycin Sulphate
39. Hydroxymycin Sulfate
40. 134235-09-9
41. Paramomycin
42. Monomycin
43. Paromomycin (tn)
44. Paromomycin Sulfate Rx346208
45. (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-(((2r,3s,4r,5s)-5-(((1r,2r,3s,5r,6s)-3,5-diamino-2-(((2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2h-pyran-3,4-diol
46. Aminosidine, Sulfate
47. Hatt & Paromomycin
48. Paromomycin [inn:ban]
49. Unii-61jjc8n5zk
50. Paromomycine [inn-french]
51. Paromomycinum [inn-latin]
52. Paromomicina [inn-spanish]
53. (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-6-hydroxy-cyclohexoxy]-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl]oxy-tetrahydropyran-3,4-diol
54. Einecs 231-423-0
55. Brn 0072285
56. Human .alpha.-1-antitrypsin & Paromomyin
57. Paromomycin [mi]
58. Paromomycin [vandf]
59. Schembl4072
60. Paromomycin [who-dd]
61. 4-18-00-07534 (beilstein Handbook Reference)
62. Chembl370143
63. Dtxsid8023424
64. Gtpl12160
65. Zinc60183170
66. Akos030489917
67. Db01421
68. Ncgc00166210-02
69. D-streptamine, O-2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-beta-d-ribofuranosyl-(1-5))-2-deoxy-
70. O-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-[o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.d-ribofuranosyl(1->5)]-2-deoxy-d-streptamine
71. C00832
72. D07467
73. Ab00639998_04
74. Neomycin Sulfate Impurity E [ep Impurity]
75. Q415625
76. Paromomycin I; Amminosidin; Catenulin; Crestomycin; Monomycin A; Neomycin E
77. (2r,3s,4r,5r,6s)-5-amino-6-{[(1r,2r,3s,4r,6s)-4,6-diamino-2-{[(2s,3r,4s,5r)-4-{[(2r,3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}-2-(hydroxymethyl)oxane-3,4-diol
78. D-streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1-.4))-2-deoxy-
79. D-streptamine, O-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-
80. Diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine
81. O-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-o-.beta.-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4))-2-deoxystreptamine
82. O-2-amino-2-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(o-2,6-diamino-2,6-dideoxy-.beta.-l-idopyranosyl-(1->3)-.beta.-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine
83. Streptamine, O-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1-3)-o-beta-d-ribofuranosyl-(1-5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1-4))-2-deoxy-
| Molecular Weight | 615.6 g/mol |
|---|---|
| Molecular Formula | C23H45N5O14 |
| XLogP3 | -8.7 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 9 |
| Exact Mass | 615.29630113 g/mol |
| Monoisotopic Mass | 615.29630113 g/mol |
| Topological Polar Surface Area | 347 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Antiprotozoal Agents
Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)
A07AA06
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07A - Intestinal antiinfectives
A07AA - Antibiotics
A07AA06 - Paromomycin
Absorption
Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.
API SUPPLIERS
Click Us!
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13576
Submission : 1998-09-01
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
A Paromomycin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Paromomycin, including repackagers and relabelers. The FDA regulates Paromomycin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Paromomycin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Paromomycin supplier is an individual or a company that provides Paromomycin active pharmaceutical ingredient (API) or Paromomycin finished formulations upon request. The Paromomycin suppliers may include Paromomycin API manufacturers, exporters, distributors and traders.
click here to find a list of Paromomycin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Paromomycin DMF (Drug Master File) is a document detailing the whole manufacturing process of Paromomycin active pharmaceutical ingredient (API) in detail. Different forms of Paromomycin DMFs exist exist since differing nations have different regulations, such as Paromomycin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Paromomycin DMF submitted to regulatory agencies in the US is known as a USDMF. Paromomycin USDMF includes data on Paromomycin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Paromomycin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Paromomycin suppliers with USDMF on PharmaCompass.
Paromomycin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Paromomycin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Paromomycin GMP manufacturer or Paromomycin GMP API supplier for your needs.
A Paromomycin CoA (Certificate of Analysis) is a formal document that attests to Paromomycin's compliance with Paromomycin specifications and serves as a tool for batch-level quality control.
Paromomycin CoA mostly includes findings from lab analyses of a specific batch. For each Paromomycin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Paromomycin may be tested according to a variety of international standards, such as European Pharmacopoeia (Paromomycin EP), Paromomycin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Paromomycin USP).
LOOKING FOR A SUPPLIER?
